Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29640280 | 0.99 | CA12 (0.37) | CA12CA9KDM4ETP53LMNA | |
| SCHEMBL20900144 | 0.83 | CA12 (0.43) | CA12CA9KDM4ETP53LMNA | |
| Hydrochloric Acid SCHEMBL21112668 | 0.82 | CA12 (0.42) | CA12CA9KDM4ETP53LMNA | |
| Hydrochloric Acid SCHEMBL21112670 | 0.82 | CA12 (0.42) | CA12CA9KDM4ETP53LMNA | |
| SCHEMBL20908218 | 0.77 | BRPF1 (0.41) | CA12CA9MEN1KMT2AMMP1 | |
| SCHEMBL21148933 | 0.77 | BRPF1 (0.41) | CA12CA9MEN1KMT2AMMP1 | |
| SCHEMBL23114826 | 0.74 | TACR1 (0.37) | LMNAPKMMEN1KMT2AMMP1 | |
| SCHEMBL21148968 | 0.74 | MEN1 (0.41) | TP53LMNAALDH1A1MAPTHPGD | |
| SCHEMBL28890357 | 0.74 | MEN1 (0.41) | TP53LMNAALDH1A1MAPTHPGD | |
| SCHEMBL21149522 | 0.73 | PTPN1 (0.41) | LMNAL3MBTL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2019075291-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | CA12 2993/4885CA9 1237/4885KDM4E 546/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | CA12 2993/4885CA9 1237/4885KDM4E 546/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | CA12 2993/4885CA9 1237/4885KDM4E 546/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | CA12 2689/4885CA9 1230/4885KDM4E 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.